{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:22:06Z","timestamp":1786990926901,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ijrobp.2024.03.009","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T05:00:50Z","timestamp":1710565250000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial"],"prefix":"10.1016","volume":"120","author":[{"given":"Binnaz","family":"Yasar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yae-Eun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam","family":"Sohaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"van As","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.03.009_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0002","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0004","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.juro.2017.02.070","article-title":"Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN\u00ae guideline","volume":"198","author":"Pompe","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional versus hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","article-title":"Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence","volume":"69","author":"Pucar","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.radonc.2021.02.008","article-title":"Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy","volume":"159","author":"Zelefsky","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0008","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0009","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0011","series-title":"Paper presented at: The 2023 American Society of Radiation Oncology (ASTRO) Annual Meeting","article-title":"5-year outcomes from PACE-B: An international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) versus conventionally fractionated or moderately hypofractionated external beam radiotherapy for localised prostate cancer","author":"van As","year":"2023"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-8-228","article-title":"Prostate stereotactic body radiotherapy with simultaneous integrated boost: Which is the best planning method?","volume":"8","author":"Tree","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0014","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0015","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0016","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ijrobp.2010.07.166","article-title":"Stereotactic radiotherapy for organ-confined prostate cancer: Early toxicity and quality of life outcomes from a multi-institutional trial","volume":"78","author":"Meier","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0017","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0018","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0019","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijrobp.2023.05.004","article-title":"Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging\u2013identified prostate cancer lesions: Results of a phase 2 trial","volume":"117","author":"Morris","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0020","first-page":"185","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0021","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0022","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","article-title":"SABR for high-risk prostate cancer: A prospective multilevel MRI-based dose escalation trial","volume":"113","author":"Hannan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0023","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0024","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2020.09.053","article-title":"Dose\u2013response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control","volume":"154","author":"Levin-Epstein","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0026","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2020.07.014","article-title":"Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients","volume":"151","author":"Levin-Epstein","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0027","first-page":"12","article-title":"High dose \u201cHDR-like\u201d prostate SBRT: PSA 10-year results from a mature, multi-institutional clinical trial","author":"Fuller","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0029","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.21.02741","article-title":"Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer: Analysis of NRG Oncology\/RTOG 9601","volume":"40","author":"Jackson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0030","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0031","first-page":"881","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): A pooled analysis of 12 randomized trials","volume":"41","author":"Martin Ma","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0032","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2023.07.004","article-title":"ReIGNITE RT boost: A prospective, international study of radiation oncologists\u2019 accuracy in contouring prostate tumors for focal radiotherapy boost on conventional MRI alone or with assistance of restriction spectrum imaging (RSI)","volume":"117","author":"Lui","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0033","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: Planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2023.07.029","article-title":"Assessing the feasibility of utilizing artificial intelligence-segmented dominant intraprostatic lesion for focal intraprostatic boost with external beam radiation therapy","volume":"118","author":"Tsui","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.03.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-023-02375-5","article-title":"Use of focal radiotherapy boost for prostate cancer: Radiation oncologists\u2019 perspectives and perceived barriers to implementation","volume":"18","author":"Zhong","year":"2023","journal-title":"Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624004255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624004255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T22:54:07Z","timestamp":1726095247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624004255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0360301624004255"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.009","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}